Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. Antivirals for influenza - historical perspectives
3. Influenza virus replication and sites of inhibition
4. Principal antiviral agents for influenza
5. Inhalation device
6. M2 inhibitors (adamantanes)
7. M2 inhibitor prophylaxis during pandemic influenza
8. Amantadine and Rimantadine - limitations
9. Detecting the emergence of resistant virus
10. Influenza prevention in households
11. Antiviral-resistant viruses with differing circulation
12. NA inhibitors for treatment
13. Oseltamivir treatment in healthy adults
14. Oseltamivir effect on return to usual activities
15. Zanamivir in adults - effect of time to treatment
16. Delayed NAI therapy in severe pandemic H1N1
17. Days of illness to treatment - outcomes
18. Oseltamivir-effect on antibiotic use, hospitalization
19. Oseltamivir studies - major outcomes
20. Oseltamivir effect in hospitalized patients
21. Adults in hospital with severe influenza - outcomes
22. Viral RNA levels in relation to onset of therapy
23. Early Oseltamivir use in pandemic H1N1 (1)
24. Early Oseltamivir use in pandemic H1N1 (2)
25. Delayed Oseltamivir Tx in high risk populations
26. Oseltamivir affects viral load - hospitalized patients
27. Upper vs lower respiratory pH1N1 viral loads
28. NAI use in severe pandemic H1N1
29. Oseltamivir treatment effects in A(H5N1) infection
30. Oseltamivir treatment and survival in H5N1
31. NA inhibitors for chemoprophylaxis
32. Influenza prevention in household contacts
33. Pandemic influenza A (H1N1) transmission, 2009
34. Oseltamivir adherence and side effects
35. Oseltamivir ring prophylaxis for pandemic H1N1
36. Post-exposure prophylaxis (PEP)
37. NAI resistance
38. Influenza antiviral resistance - general comments
39. Neuraminidase inhibitors
40. NA inhibitor resistance profiles
41. Oseltamivir resistance in N1 (H275Y)
42. Antiviral resistance, seasonal H1N1, Hong Kong
43. Oseltamivir-resistant seasonal A(H1N1), 2007-9
44. Resistant vs. susceptible viral titers
45. Oseltamivir resistance in pandemic H1N1
46. Oseltamivir resistance in pandemic H1N1, 2010
47. Post therapy Oseltamivir-resistance in H1N1
48. Resistance in oncology/hematology patients
49. Oseltamivir resistance (H275Y) in pandemic H1N1
50. Viral loads during Oseltamivir treatment of H5N1
51. Sequential NAI resistance emergence in IC host
52. Influenza antiviral resistance - comments
53. Newer and investigational influenza antivirals
54. Investigational anti-influenza agents
55. Anti-influenza agents in clinical development, 2010
56. Summary of recent NAI clinical trials
57. Resolution of Oseltamivir-resistant H1N1 - children
58. IV Zanamivir for Oseltamivir-resistant H1N1
59. IV Zanamivir for hospitalized patients with A/H1N1
60. Neutralizing antibody against pandemic A/H1N1
61. Neutralizing monoclonal Abs cross-protective
62. Therapeutic efficacy of anti-HA Abs for H1N1
63. Studying the host inflammatory response
64. Impaired immune responses in severe illness
65. Antiviral combinations
66. Antivirals combinations - preclinical findings
67. Combination antiviral therapies in influenza
68. Combined therapy with Zanamivir and Rimantadine
69. Combined Oseltamivir and inhaled Zanamivir
70. Combined Tx - Amantadine, Ribavirin, Oseltamivir
71. Antivirals for influenza - comments

Topics Covered

• Antivirals for influenza-historical perspectives
• Influenza virus replication and sites of inhibition
• Principal antiviral agents for influenza
• Detecting the emergence of resistant virus
• Influenza prevention in households
• Antiviral-resistant viruses with differing circulation
• NA inhibitors for treatment
• NA inhibitors for chemoprophylaxis
• Post-exposure prophylaxis (PEP)
• NAI resistance
• Newer and investigational influenza antivirals
• Antiviral combinations

Links

Series:

• Antivirals

Categories:

• Clinical Practice
• Microbiology
• Pharmaceutical Sciences

Therapeutic Areas:

• Infectious Diseases

Talk Citation

Publication History

• Published on August 31, 2011

Financial Disclosures

• Prof. Frederick G. Hayden has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.